Integra LifeSciences Holdings (IART)vsNovartis AG ADR (NVS)
IART
Integra LifeSciences Holdings
$16.99
-3.25%
HEALTHCARE · Cap: $1.22B
NVS
Novartis AG ADR
$148.38
-0.99%
HEALTHCARE · Cap: $273.77B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 3340% more annual revenue ($56.58B vs $1.64B). NVS leads profitability with a 23.9% profit margin vs -30.1%. IART appears more attractively valued with a PEG of 0.71. IART earns a higher WallStSmart Score of 52/100 (C-).
IART
Buy52
out of 100
Grade: C-
NVS
Hold49
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+86.2%
Fair Value
$81.09
Current Price
$16.99
$64.10 discount
Margin of Safety
-62.1%
Fair Value
$91.39
Current Price
$148.38
$56.99 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Growing faster than its price suggests
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Areas to Watch
2.4% revenue growth
0.4% earnings growth
Smaller company, higher risk/reward
Elevated debt levels
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Revenue declined 0.7%
Comparative Analysis Report
WallStSmart ResearchBull Case : IART
The strongest argument for IART centers on Price/Book, PEG Ratio. PEG of 0.71 suggests the stock is reasonably priced for its growth.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bear Case : IART
The primary concerns for IART are Revenue Growth, EPS Growth, Market Cap. Debt-to-equity of 1.96 is elevated, increasing financial risk.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, Debt/Equity, PEG Ratio.
Key Dynamics to Monitor
IART profiles as a turnaround stock while NVS is a declining play — different risk/reward profiles.
IART carries more volatility with a beta of 1.08 — expect wider price swings.
IART is growing revenue faster at 2.4% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
IART scores higher overall (52/100 vs 49/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Integra LifeSciences Holdings
HEALTHCARE · MEDICAL DEVICES · USA
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, limb reconstruction, orthopedics, and general surgery. The company is headquartered in Princeton, New Jersey.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?